2d agoInvesting.com Analyst RatingsBULLISH 56General
Needham reiterates Buy on TransMedics stock, names new CFO
Needham reiterates Buy on TransMedics stock, names new CFO
Archived explainer. For the current picture see today's TMDX page.
Why Is TRANSMEDICS GROUP IN (TMDX) Stock Down Today?
By the Top Tier Newswire AI Desk · September 11, 2026 at 10:33 AM ET · reviewed against 7 wire stories
TRANSMEDICS GROUP IN (TMDX) is down -5.59% in the latest session. Our newswire has captured 7 stories on TMDX across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 55/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
TMDX stock is down 5.59% to $80.29 as of the latest trade, marking a sharp reversal after opening near $85. The primary driver of the decline is the mixed reaction to the appointment of new CFO Fernando Araujo and the company’s reaffirmed 2026 revenue guidance. While TransMedics reiterated its full-year revenue forecast of $737 million to $757 million, the stock has faced downward pressure amid conflicting analyst price targets and a sell-off by a board member.
What Happened
TransMedics announced the appointment of Fernando Araujo, previously of GE HealthCare, as its new chief financial officer, effective September 21. Araujo succeeds Gerardo Hernandez, and the company emphasized continuity in its 2026 financial outlook. The firm also filed an SEC 8-K disclosing the leadership change and related compensation arrangements. Despite the strategic hire, the stock opened at $85 and quickly reversed, hitting a session high of $86.99 before falling to a low of $80.10. The stock closed the session near its low, with volume at 0.2 million shares, well below its 3-month average.
Analysts have responded with divergent views. Needham and TD Cowen reiterated Buy ratings, with the latter maintaining a $120 price target. Piper Sandler cut its price target to $100 while keeping an Overweight rating. UBS, however, lowered its target to $77 and maintained a Neutral stance. These conflicting signals may have contributed to the stock’s volatility.
What The Data Shows
The stock is trading within its 52-week range of $60.10 to $156.00, having printed 19 fresh 52-week lows on the same day. Recent insider activity includes a $722,000 sell disclosed by a director on June 17. TransMedics has a market cap of $3.0 billion, a P/E ratio of 21.2, and trailing 12-month revenue growth of 25.8%. Despite a strong net margin of 22.7%, the stock’s beta of 1.88 suggests it is more volatile than the broader market.
What To Watch
TransMedics has no upcoming earnings date in the provided data. Investors should monitor the breadth of analyst coverage and any further changes in price targets or institutional sentiment.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TMDX by the numbers
Last: $80.29Session: -5.59%Coverage: 7 stories / 6 sourcesAI sentiment: 55/100 (mixed)Mkt cap: $3.0BP/E: 21.252w: $60.10 to $156.00
The headlines behind the move
2d agoMarketWatchBULLISH 56General
TransMedics Names GE HealthCare's Araujo as CFO, Backs Revenue Forecast
2d agoSEC 8-KNEUTRAL 50General
TransMedics Group, Inc. (TMDX) files 8-K
Filed: 2026-09-10 AccNo: 0001193125-26-387960 Size: 181 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
2d agoSeeking AlphaBULLISH 55General
TransMedics appoints new finance chief
TMDX appointed Fernando Araujo as chief financial officer, effective Sept. 21, succeeding Gerardo Hernandez.
2d agoThe FlyBULLISH 56General
TransMedics appoints Fernando Araujo as CFO
2d agoThe FlyBULLISH 56Earnings
TransMedics backs 2026 revenue view $737M-$757M, consensus $741.71M
2d agoPR NewswireBULLISH 56General
TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
ANDOVER, Mass., Sept. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief Financial Officer, effective September 21,...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on TMDX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier TMDX move explainers: 2026-09-11